Laverock Therapeutics Reports Key Oncology Research Milestones
In-vivo functional studies support lead programme selection
Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo functional milestones across its T-cell and macrophage oncology programmes for solid tumour indications. The data support lead programme selection and progression towards the clinic.
Laverock’s platform technology enables programmable, tunable and multiplex gene control for both endogenous targets and for transgenically expressed payloads. In its T-cell programme (LVK201), the platform is designed to improve CAR-T cell anti-tumour activity without compromising safety. The latest data from ovarian cancer models, presented at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting in May, demonstrate that the Company’s technology can improve solid tumour control by targeting three distinct immunomodulatory pathways simultaneously. Previous studies have also shown that, because the technology harnesses T-cell activation dynamics to act only when needed, safety can be significantly improved compared with alternative approaches.
